Synthesis and Pharmacological Characterization of 3-[2-((3a<i>R</i>,9b<i>R</i>)-<i>cis</i>-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1<i>H</i>- benz[<i>e</i>]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-<i>d</i>]pyrimidine- 2,4(1<i>H</i>,3<i>H</i>)-dione (A-131701):  A Uroselective α<sub>1A</sub> Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia

Synthesis and Pharmacological Characterization of 3-[2-((3a<i>R</i>,9b<i>R</i>)-<i>cis</i>-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1<i>H</i>- benz[<i>e</i>]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-<i>d</i>]pyrimidine- 2,4(1<i>H</i>,3<i>H</i>)-dione (A-131701):  A Uroselective α<sub>1A</sub> Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia